MD Anderson researchers present encouraging results of early-stage...
CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show...
Ultrasound-guided microbubbles boost immunotherapy efficacy
Researchers at The University of Texas MD Anderson Cancer Center have developed an ultrasound-guided cancer immunotherapy platform...
MD Anderson and Community Health Network announce...
The University of Texas MD Anderson Cancer Center and Indianapolis-based Community Health Network today announced a partnership...
Therapies targeting DNA damage response show promising antitumor...
NEW ORLEANS ― Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers —...
MD Anderson Research Highlights: SGO 2022 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational...
MD Anderson renews partnership with Banner Health
The University of Texas MD Anderson Cancer Center announced today its first-ever partnership renewal with Banner Health, which created...
Trametinib represents potential new standard-of-care for...
A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the...
Serial radiation therapy is safe and effective as...
In a new single-arm study, researchers at The University of Texas MD Anderson Cancer Center reported that radiation therapy as...
Anil Sood, M.D., elected to the National Academy of Medicine
Anil Sood, M.D., professor of Gynecologic Oncology and Reproductive Medicine, has been elected to the National Academy of Medicine...
ATR inhibitor RP-3500 demonstrates safety and early...
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered that ATR inhibitor...